Curcumin Added to Ongoing Treatment for Cognitive Difficulties in Schizophrenia
About this title
Read the official source — NCT02104752Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- VA Greater Los Angeles Healthcare System
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02104752
- Official title
Show the full official title
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Los Angeles
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is VA Greater Los Angeles Healthcare System.
Did this study involve medication?
Yes. The study involved medication, including Curcumin and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
